Ischemia DOES matter! Revascularization DOES impact outcomes!
Check the latest work led by Giuseppe Panuccio: perfect saturday ready, to be matched with the ORBITA-2 Just released ad #AHA23 !
Dean Torella SABOURETCardiologist Michael Savage Rasha Al-Lamee
doi.org/10.1016/j.hjc.…

Circulating invariant Natural Killer T cells and incident coronary events: check the new evidence on #EHJOpen ! bit.ly/3G763NK
Lavinia Baciu Magnus Bäck Daniel Ketelhuth Translational Cardiology

🔝🔝🔝Session at #PCRLV
On #challenges in #TAVI
⭐️how to manage CAD and AS
⭐️tip & trick on how to reaccess coronaries after TAVI
⭐️how to manage VHD in CS
⭐️come to #EAPCI booth and beacons #EAPCI member

#DAPA -MI : #Dapagliflozin shows promising outcomes!

In a study of 4017 patients, dapagliflozin outperformed placebo (win ratio 1.34, P<0.001) in a composite of cardiometabolic outcomes.

However, in terms of reducing CV death/🏥, it's similar to placebo (2.5% vs 2.6%, HR 0.95.…

Ischemia DOES matter! Revascularization DOES impact outcomes!
Check the latest work led by Giuseppe Panuccio: perfect saturday ready, to be matched with the ORBITA-2 Just released ad #AHA23 !
Dean Torella SABOURETCardiologist Michael Savage Rasha Al-Lamee
doi.org/10.1016/j.hjc.…

Metabolic syndrome cardiovascular risk prevention by omega-3 polyunsaturated fatty acids
👉How can we prevent metabolism-related CVrisk? Read the expert opinion
academic.oup.com/ehjopen/advanc…
#OpenUpYourScience Salvatore De Rosa Magnus Bäck Istituto Mario Negri Silvia Castelletti CVPrevInterv

Caloric restriction and markers of senescence/SaSP onlinelibrary.wiley.com/doi/full/10.11…

AHA 2023 – Day2 interviews about #LBS by #CNCFcardio experts #AHA23 cncf.eu/aha-2023-jour-…

Read the Editorial piece by Magnus Bäck and Prof. Roberto Latini, simultaneously published with the #AHA23 presentation of the REDUCE-IT MetSyn study!
#OpenUpYourScience with #EHJOpen !
Magnus Bäck Istituto Mario Negri Silvia Castelletti CVPrevInterv

Secondary prevention or treatment of hypertriglyceridemia? Read the experts' view on EHJOpen Editor-in-Chief!
#OpenUpYourScience with #EHJOpen !
Magnus Bäck Henry Han Dr Anastasia Mihailidou FAHA FCSANZ FESC Hany Ragy

Effectiveness of Icosapent Ethyl on First and Total CV Events in Patients with Metabolic Syndrome, but without Diabetes: REDUCE-IT MetSyn European Society of Cardiology Journals
academic.oup.com/ehjopen/advanc…
#AHA23 #OpenUpYourScience , #EHJOpen !

#AHA23 #Cardiology #CardioTwitter EHJOpen Editor-in-Chief European Society of Cardiology Journals

Check out our new study presented at #AHA2023 & published in EHJOpen Editor-in-Chief on IPE benefit in #Mets Dr. Deepak L. Bhatt Penn Cardiology Penn Medicine American Heart Association - Pennsylvania University of Maryland Cardiology Ph.Gabriel Steg Ellen Beth Levitt Christie Ballantyne Amarin ASPC National Lipid Association American Heart MD Eliot Brinton

New study confirms efficacy of #CRISPR -based drug to decrease LP(a) values at the #AHA23 Congress: exciting times ahead!

Editorial in EHJOpen Editor-in-Chief by Magnus Bäck and Roberto Latini Istituto Mario Negri on #CVD #inflammation in metabolic syndrome. #AHA23 Salvatore De Rosa Lavinia Baciu academic.oup.com/ehjopen/articl…

Great pleasure and honor to discuss the changing landscape in TTM after OHCA at #AHA23 with fantastic colleagues Carolina Malta Hansen Sean van Diepen Christopher Barnett MD, MPH, FACC Dr. Jason Bartos Carlos L. Alviar MD, FACC AHA Science 3CPR Council BalimSenman Jason N. Katz ACVCPresident